Eisai to trial orexin-2 receptor agonist in narcolepsy patients [Yahoo! Finance]
NLS Pharmaceutics Ltd. - Common Shares (NLSP)
Company Research
Source: Yahoo! Finance
Narcolepsy is a rare long-term brain condition that can prevent a person from choosing when to wake or sleep. It is characterised by excessive daytime sleepiness. Type 1 narcolepsy accounts for 20% of total narcolepsy cases and is characterised by the presence of cataplexy, a sudden loss of muscle tone while a person is awake. The double-blind, placebo-controlled Phase I trial (NCT06462404) is expected to enrol approximately 40 adult patients with narcolepsy type 1. The study will assess three dose strengths of E2086 in a five-period, single-dose crossover study, using objective and patient-reported wake promotion measures to evaluate its efficacy and safety. The study's primary endpoints include mean sleep latency, defined as the amount of time a person takes to fall asleep, measured using the maintenance of wakefulness test (MWT). The mean sleep latency will be measured at five different time points – days one, five, nine, 13 and 17. E2086 is a selective orexin-2 receptor ago
Show less
Read more
Impact Snapshot
Event Time:
NLSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NLSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NLSP alerts
High impacting NLS Pharmaceutics Ltd. - Common Shares news events
Weekly update
A roundup of the hottest topics
NLSP
Sec Filings
- 9/25/24 - Form 6-K
- 9/19/24 - Form 6-K
- 9/17/24 - Form 6-K
- NLSP's page on the SEC website